Literature DB >> 11361186

Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis.

P Rahman1, E Nguyen, C Cheung, C T Schentag, D D Gladman.   

Abstract

OBJECTIVE: To compare the radiological severity of patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA).
METHODS: Patients were identified from the University of Toronto PsA and RA databases. Using the earliest available radiographs, each RA patient was matched to a single PsA patient on the basis of sex, age, and disease duration. Two rheumatologists blinded to the patient's diagnosis scored the radiographs using the modified Steinbrocker method.
RESULTS: PsA and RA groups were similar with respect to demographics as well as the use of disease modifying antirheumatic medications. No significant difference in Steinbrocker score for the hands and feet or the hands only was noted. Patients with RA had a higher radiological score in the feet. The 2 groups were similar in the number of joints with significant radiological damage (Steinbrocker 3 and 4). CONCLUSION; Overall the radiological severity in the hands and feet of patients with PsA was comparable to that of patients with RA.

Entities:  

Mesh:

Year:  2001        PMID: 11361186

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  27 in total

Review 1.  [Radiological differential diagnosis of rheumatoid arthritis].

Authors:  M C Wick; A S Klauser
Journal:  Radiologe       Date:  2012-02       Impact factor: 0.635

Review 2.  Psoriatic arthritis and imaging.

Authors:  P A Ory; D D Gladman; P J Mease
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 3.  Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases?

Authors:  D D Gladman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

4.  Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment.

Authors:  A W R van Kuijk; P Reinders-Blankert; T J M Smeets; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

5.  The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.

Authors:  A Kavanaugh; C E Antoni; D Gladman; S Wassenberg; B Zhou; A Beutler; G Keenan; G Burmester; D E Furst; M H Weisman; J R Kalden; J Smolen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

6.  Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.

Authors:  D D Gladman; P J Mease; M A Cifaldi; R J Perdok; E Sasso; J Medich
Journal:  Ann Rheum Dis       Date:  2006-10-17       Impact factor: 19.103

Review 7.  Radiographic scoring methods in rheumatoid arthritis and psoriatic arthritis.

Authors:  Fausto Salaffi; Marina Carotti; Giacomo Beci; Marco Di Carlo; Andrea Giovagnoni
Journal:  Radiol Med       Date:  2019-02-09       Impact factor: 3.469

8.  Which Psoriasis Patients Develop Psoriatic Arthritis?

Authors:  Kristine Busse; Wilson Liao
Journal:  Psoriasis Forum       Date:  2010

9.  Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.

Authors:  A Kavanaugh; C Antoni; G G Krueger; S Yan; M Bala; L T Dooley; A Beutler; C Guzzo; D Gladman
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

10.  MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage.

Authors:  Yu M Tan; Mikkel Østergaard; Anthony Doyle; Nicola Dalbeth; Maria Lobo; Quentin Reeves; Elizabeth Robinson; William J Taylor; Peter B Jones; Karen Pui; Jamie Lee; Fiona M McQueen
Journal:  Arthritis Res Ther       Date:  2009-01-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.